Recommended content

Organigram makes THCV investment in US cannabis genetics company Phylos

Canadian producer Organigram Holdings is investing as much as $8 million in Portland, Oregon-based cannabis genetics and seeds company Phylos Bioscience.

Under the deal, Organigram will shift to producing cannabis from seed and create new products containing the minor cannabinoid THCV.


Organigram also will become “the first Canadian licensed producer to release high potency whole plant derived THCV in Canada based on Phylos’ genetics platform,” the Moncton, New Brunswick, company said in a news release.

Organigram said the deal will:

Allow the company “to modernize cannabis production and employ seed-based production at scale.” Provide access to “proprietary genetic identification tools” to boost development of proprietary cannabis cultivars. Permit Organigram to develop new genetics for its brands such as Shred, “providing future opportunities to offer ‘turn-key’ U.S. and international licensing of seed-based genetics and an established cannabis brand when and where legal.”

“We know

Read full article on Marijuana Business Daily

Follow us on Instagram or join us on facebook page

Be first to rate

Marijuana Business Daily

More news